AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1101065 — intervention group
Group type: COMPARATOR
Intervention: Control human immune globulin preparation
Number of subjects: 58
Study 31015036 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteogenomic variant database created from pooled sequencing experiments
Number of subjects: 137
Study 31015036 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteogenomic variant database with 4 complete genomes
Number of subjects: 137
Study 31015036 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteogenomic variant database with 26 assemblies
Number of subjects: 137
Study 31015036 — intervention group
Group type: COMPARATOR
Intervention: Conventional databases
Number of subjects: 137
Study 28158993 — intervention group
Group type: COMPARATOR
Intervention: FSGS
Number of subjects: 49
Study 28158993 — intervention group
Group type: EXPERIMENTAL
Intervention: MCD
Number of subjects: 49
Study 26485297 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 83
Study 26485297 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 83
Study 23883377 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 261
Study 23883377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 21771261 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (CTr) for 15 weeks
Number of subjects: 15
Study 21771261 — intervention group
Group type: COMPARATOR
Intervention: Retraining (RTr) after a 3-week detraining period
Number of subjects: 15
Study 19650752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 493
Study 19650752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 493
Study 19650752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 19650752 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 493
Study 16431185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 280
Study 16431185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 15561379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular analgesics (short acting anaesthetics)
Number of subjects: 219
Study 15561379 — intervention group
Group type: COMPARATOR
Intervention: No postoperative analgesia until moderate-to-severe pain was documented
Number of subjects: 219
Study 11368732 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice per day)
Number of subjects: 164
Study 11368732 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (400 microg twice per day)
Number of subjects: 164
Study 11368732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 9164377 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol intervention (nortriptyline hydrochloride or interpersonal psychotherapy)
Number of subjects: 0
Study 9164377 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol treatment completion
Number of subjects: 0
Study 9164377 — intervention group
Group type: COMPARATOR
Intervention: Usual care with the patient's physician
Number of subjects: 0
Study 8706197 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.25 mg x kg(‐1)
Number of subjects: 75
Study 8706197 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg x kg(‐1)
Number of subjects: 75
Study 8706197 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg x kg(‐1)
Number of subjects: 75
Study 8706197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.0 mg x kg(‐1) edrophonium)
Number of subjects: 75
Study 2243544 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based reminders
Number of subjects: 0
Study 2243544 — intervention group
Group type: COMPARATOR
Intervention: Two other interventions
Number of subjects: 0
Study 115159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 12
Study 115159 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliquidone
Number of subjects: 12
Study 115159 — intervention group
Group type: EXPERIMENTAL
Intervention: Glisoxepide
Number of subjects: 12
Study 115159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29279189 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate intake with water
Number of subjects: 12
Study 29279189 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate intake with orange juice
Number of subjects: 12
Study 29279189 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate intake with breakfast
Number of subjects: 12
Study 27715368 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal imitation training (RIT)
Number of subjects: 20
Study 28270319 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking in a semi-natural recreational area
Number of subjects: 0
Study 28270319 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking on a treadmill in a gym
Number of subjects: 0
Study 28270319 — intervention group
Group type: COMPARATOR
Intervention: Sitting and watching nature-based videos on TV
Number of subjects: 0
Study 24034810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting-Down-Programme (CDP)
Number of subjects: 80
Study 24034810 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 80
Study 21123186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1782
Study 21123186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1782
Study 19484416 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional analysis of the maxilla in patients with bilateral cleft lip and palate
Number of subjects: 32
Study 19484416 — intervention group
Group type: COMPARATOR
Intervention: Eugnathic control group, n=32, mean age 5.02 years
Number of subjects: 32
Study 17947502 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration IH (LDIH) protocol: daily 60-min exposures to normobaric 12% O(2)
Number of subjects: 10
Study 17947502 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration IH (SDIH) protocol: twelve 5-min bouts of 12% O(2), separated by 5-min bouts of room air, daily
Number of subjects: 10
Study 17947502 — intervention group
Group type: COMPARATOR
Intervention: Both LDIH and SDIH
Number of subjects: 10
Study 15139073 — intervention group
Group type: EXPERIMENTAL
Intervention: HEC
Number of subjects: 298
Study 15139073 — intervention group
Group type: EXPERIMENTAL
Intervention: MEC
Number of subjects: 298
Study 15139073 — intervention group
Group type: COMPARATOR
Intervention: Physician/Nurse Predictions
Number of subjects: 298
Study 11574733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 12
Study 11574733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemophan membrane
Number of subjects: 12
Study 11574733 — intervention group
Group type: COMPARATOR
Intervention: Modified cellulose membrane
Number of subjects: 12
Study 8679424 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG 4 liters
Number of subjects: 80
Study 8679424 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate 3 packets plus one microenema
Number of subjects: 80
Study 1889968 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren)
Number of subjects: 49
Study 1889968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Nidilat)
Number of subjects: 49
Study 1889968 — intervention group
Group type: COMPARATOR
Intervention: Tropenzilium bromide (Palerol)
Number of subjects: 49
Study 6830410 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (average, 40 mg/day for up to four years)
Number of subjects: 86
Study 6830410 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive thioridazine hydrochloride (mean, 87 mg/day)
Number of subjects: 86
Study 6830410 — intervention group
Group type: COMPARATOR
Intervention: General population norms
Number of subjects: 86
Study 30609411 — intervention group
Group type: EXPERIMENTAL
Intervention: Caralluma fimbriata extract (CFE) 500 mg b.d. (n = 49)
Number of subjects: 97
Study 30609411 — intervention group
Group type: COMPARATOR
Intervention: Placebo 500 mg b.d. (n = 48)
Number of subjects: 97
Study 29982386 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 0
Study 29982386 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 0
Study 26540363 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthread design on coronal portion of the fixture (Implantium)
Number of subjects: 30
Study 26540363 — intervention group
Group type: COMPARATOR
Intervention: Without microthread design (Superline)
Number of subjects: 30
Study 26540363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Microthread and Control)
Number of subjects: 30
Study 24123098 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive low-density lipoprotein (LDL)‐lowering therapy with LDL‐apheresis
Number of subjects: 0
Study 24123098 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy
Number of subjects: 0
Study 22958580 — intervention group
Group type: EXPERIMENTAL
Intervention: succinylcholine
Number of subjects: 96
Study 22958580 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium
Number of subjects: 96
Study 22958580 — intervention group
Group type: COMPARATOR
Intervention: no muscle relaxant
Number of subjects: 96
Study 18840313 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% glucose solution
Number of subjects: 12
Study 18840313 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% glucose solution
Number of subjects: 12
Study 17993364 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 50 mg twice daily and placebo manipulative therapy
Number of subjects: 240
Study 17993364 — intervention group
Group type: EXPERIMENTAL
Intervention: spinal manipulative therapy and placebo drug
Number of subjects: 240
Study 17993364 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 50 mg twice daily and spinal manipulative therapy
Number of subjects: 240
Study 17993364 — intervention group
Group type: COMPARATOR
Intervention: double placebo
Number of subjects: 240
Study 16307219 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy
Number of subjects: 60
Study 16307219 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 60
Study 11942978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy (102 patients)
Number of subjects: 155
Study 11942978 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone (53 patients)
Number of subjects: 155
Study 9706930 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge Whitacre spinal needle
Number of subjects: 30
Study 9706930 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge Quincke spinal needle
Number of subjects: 30
Study 7871143 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (telephone reminder from the nurse plus written materials)
Number of subjects: 239
Study 7871143 — intervention group
Group type: COMPARATOR
Intervention: Passive intervention (letter and leaflet encouraging immunisation)
Number of subjects: 239
Study 7871143 — intervention group
Group type: COMPARATOR
Intervention: Passive intervention
Number of subjects: 239
Study 2406439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis (3 doses of 2g each: initial dose after cord clamping, subsequent doses at 4 and 8 hours)
Number of subjects: 0
Study 2406439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin prophylaxis
Number of subjects: 0
Study 7004400 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 51
Study 7004400 — intervention group
Group type: COMPARATOR
Intervention: Hand sutures
Number of subjects: 51
Study 31409381 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-first arm (4-week PA intervention followed by 4-week FVC intervention)
Number of subjects: 556
Study 31409381 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC-first arm (4-week FVC intervention followed by 4-week PA intervention)
Number of subjects: 556
Study 31409381 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + FVC simultaneous arm (8-week intervention addressing both PA and FVC)
Number of subjects: 556
Study 31409381 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control arm (8 weeks of general health information)
Number of subjects: 556
Study 28861803 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) treatment
Number of subjects: 32
Study 28861803 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention (PI)
Number of subjects: 32
Study 28861803 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 32
Study 24209774 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 49
Study 24209774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23646916 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching interviewer‐interviewee instructions (providing or obtaining as much information as possible or only accurate information) in Experiment 1.
Number of subjects: 83
Study 23646916 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to corroborating eyewitness identifications in Experiment 2.
Number of subjects: 83
Study 21771668 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 BV (bacterial lysate prophylaxis)
Number of subjects: 63
Study 21771668 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic regimen (Control)
Number of subjects: 63
Study 19390752 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 800 mg/day
Number of subjects: 69
Study 19390752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 17551159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4447
Study 17551159 — intervention group
Group type: COMPARATOR
Intervention: Control (metformin plus sulfonylurea)
Number of subjects: 4447
Study 15167084 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.15 mg/kg b.i.d.
Number of subjects: 24
Study 15167084 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.30 mg/kg b.i.d.
Number of subjects: 24
Study 15167084 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.60 mg/kg b.i.d.
Number of subjects: 24
Study 15167084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11446724 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol potassium chloride)
Number of subjects: 150
Study 11446724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9786373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visitation during pregnancy and postnatally
Number of subjects: 315
Study 8169187 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg caffeine
Number of subjects: 21
Study 8169187 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg caffeine
Number of subjects: 21
Study 8169187 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (both dosages)
Number of subjects: 21
Study 3477659 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (15 mg or 50,000 IU), riboflavin (200 mg), and zinc (50 mg)
Number of subjects: 610
Study 3477659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 3477659 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol, riboflavin, and zinc
Number of subjects: 610
Study 28936715 — intervention group
Group type: EXPERIMENTAL
Intervention: Action-line partograph
Number of subjects: 384
Study 28936715 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-line partograph
Number of subjects: 384
Study 28183047 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of an ellagitannin-containing pomegranate extract (PE) daily
Number of subjects: 35
Study 28183047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 35
Study 26322819 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry monitoring
Number of subjects: 161
Study 26322819 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pulse oximetry monitoring
Number of subjects: 161
Study 22832034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 10 mg (6-11 years)
Number of subjects: 59
Study 22832034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg (12-17 years)
Number of subjects: 59
Study 22832034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 0.5 mg/kg (0-1 month)
Number of subjects: 59
Study 22832034 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (various doses)
Number of subjects: 59
Study 19884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity RPSS (2-hour sessions, 3 times a week for 1 month)
Number of subjects: 22
Study 19884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity RPSS (2-hour sessions, 3 times a week for 1 month)
Number of subjects: 22
Study 19884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity RPSS
Number of subjects: 22
Study 19884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity RPSS
Number of subjects: 22
Study 19884642 — intervention group
Group type: EXPERIMENTAL
Intervention: RPSS (both intensities)
Number of subjects: 22
Study 17392726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 0.01 mg/kg
Number of subjects: 13
Study 17392726 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 0.3 mg/kg
Number of subjects: 13
Study 17392726 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study 17392726 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 mcg/kg/min
Number of subjects: 13
Study 17392726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 13
Study 17392726 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 13
Study 16372226 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-fat/moderate-carbohydrate diet
Number of subjects: 40
Study 16372226 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/high-carbohydrate diet
Number of subjects: 40
Study 12065339 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg bid for 6 weeks
Number of subjects: 55
Study 12065339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 9469367 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral granisetron (2 mg)
Number of subjects: 1085
Study 9469367 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ondansetron (32 mg)
Number of subjects: 1085
Study 7648772 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (400 mg single dose)
Number of subjects: 11
Study 7648772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7648772 — intervention group
Group type: COMPARATOR
Intervention: Entacapone and Placebo
Number of subjects: 11
Study 2652209 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antibiotic prophylaxis for 48 h with sodium cefuroxim, 1.5 g the first dose and subsequent doses of 750 mg iv
Number of subjects: 179
Study 2652209 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective antibiotic prophylaxis based on determination of preoperative gastric pH (pH < 4, no antibiotic prophylaxis; pH > 4, prophylaxis as in group I)
Number of subjects: 179
Study 2652209 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy beginning postoperatively with cefuroxim 750 mg every 78 h for 4 days
Number of subjects: 179
Study 2652209 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific prophylaxis mentioned)
Number of subjects: 179
Study 817696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (3 to 6 mg daily) combined with previous antiepileptic drugs
Number of subjects: 20
Study 817696 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with previous antiepileptic drugs
Number of subjects: 20
Study 817696 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 20
Study 31842788 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous suture
Number of subjects: 134
Study 31842788 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 134
Study 30355322 — intervention group
Group type: EXPERIMENTAL
Intervention: AADvac1 (active immunotherapy against tau protein pathology)
Number of subjects: 26
Study 27119580 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro 200 U/mL (IL200)
Number of subjects: 38
Study 27119580 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro 100 U/mL (IL100)
Number of subjects: 38
Study 24520362 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (3 times a week for 4 weeks)
Number of subjects: 28
Study 22205311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened soft drinks (SSSDs) (regular cola)
Number of subjects: 47
Study 22205311 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric semiskim milk
Number of subjects: 47
Study 22205311 — intervention group
Group type: COMPARATOR
Intervention: Aspartame-sweetened diet cola
Number of subjects: 47
Study 22205311 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 47
Study 20695726 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-core biopsy
Number of subjects: 233
Study 20695726 — intervention group
Group type: COMPARATOR
Intervention: 12-core biopsy
Number of subjects: 233
Study 17481947 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal therapy for advanced chronic heart failure (specific intervention details not provided)
Number of subjects: 0
Study 15795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intake in women using HRT
Number of subjects: 228
Study 15795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake in women not using HRT
Number of subjects: 228
Study 15795448 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intake in women using HRT in the lowest tertile of calcium intake
Number of subjects: 228
Study 12070751 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 27